The shadow of generic rivalry has repeatedly loomed around copyright’s famous drug, PDE5 Inhibitor, sparking questions about the future of related drug stakes. While early periods saw substantial returns, the patent expiration has allowed the way for discounted substitutes, possibly diminishing revenue and posing a significant danger for investor